Type a search term to find related articles by LIMS subject matter experts gathered from the most trusted and dynamic collaboration tools in the laboratory informatics industry.
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm.[1][2]
They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD).[3] It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants.[4]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
LiMSforum.com © . All Rights Reserved by JetSoft, Inc.
LIMS forum content by LIMS forum members is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at www.limsforum.com.